Recce Pharmaceuticals Ltd (RCE.AX)
| Previous Close | 0.6500 |
| Open | 0.6400 |
| Bid | 0.6350 x 55200 |
| Ask | 0.6500 x 1644700 |
| Day's Range | 0.6400 - 0.6550 |
| 52 Week Range | 0.4100 - 0.7772 |
| Volume | |
| Avg. Volume | 164,714 |
| Market Cap | 130.529M |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRecce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. “We thank the China National Intellectual Property Administration for their recognition of the signific
- GlobeNewswire
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeksR327 dosed at 3,000mg has successfully been tested at various infusion times (15, 20, 30, 45 minutes, and 1 hour)Minimum Inhibitory Concentration (MIC) activity identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuti
- GlobeNewswire
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP standards in support of current and anticipated clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) SYDNEY, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic an
